Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 2006

View Archived Issues

Cimetidine's potential for cancer treatment reviewed

ProEthic plans pain relief product launches for 2008

1-TDC inhibits bacteria and enzymes associated with inflammatory conditions

Chelsea Therapeutics and Active Biotech sign codevelopment agreement

Maxygen achieves milestone in Roche factor VIIa collaboration

ThermoDox development advances on several fronts

CSA-13 demonstrates efficacy in eradicating a MRSA biofilm

Nonhuman primate data on PPI-2458 made available

MyVax idiotype immunotherapy studied in phase I/II study for CLL

Tranzyme completes phase I study of ghrelin receptor agonist TZP-101

Prana plans phase IIa study of PBT-2 in Alzheimer's disease patients

Fast track designation for Shigamabs dual antibody product

Sirna Therapeutics licenses microRNA technology from UMMS

ISIS-5320 shows potential as anti-HIV topical microbicide

Uvidem appears safe in phase II melanoma trial

Collidem induces immune responses in patients with metastatic colorectal cancer

VP-025 reduces retinal inflammation in experimental diabetic retinopathy

German report questions therapeutic benefit of Exubera

Avantogen and Hawaii Biotech combine vaccine businesses

Genentech extends Curis Hedgehog funding

Phase IIb trial studies IPL-512602 in moderate to severe asthma

Second phase III trial begins for pancreatic enzyme product EUR-1008

Kaken licenses antifungal compound KP-103 to Dow

Preclinical and clinical update on NeuGene antisense compound for HCV

Japanese launch of Femara

Recent GSK and Boehringer Ingelheim patents report novel agents for HIV infection

Recent patents impart new therapeutic agents for cancer

FDA approval for smoking cessation therapy Chantix

Natural products show potential to prevent skin photoaging

Novel dual PPARgamma and delta agonist shows antiatherosclerotic potential in vitro

Schering, Berlex develop compounds that inhibit T-cell but not LPS-mediated TNF-alpha production